Optimal LDCT screening for never-smoking Asian women using integrated polygenic and environmental risk: a microsimulation modelling study
This microsimulation study demonstrates that tailoring low-dose CT screening initiation ages and intervals based on integrated polygenic risk scores and environmental tobacco smoke exposure maximizes cost-effective lung cancer mortality reduction for never-smoking Asian women, challenging current guidelines that rely solely on smoking history.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Lung cancer has long been viewed as a disease driven primarily by smoking, leading to screening guidelines that focus almost exclusively on heavy smokers. However, a different reality is unfolding in East Asia, where a significant number of women who have never smoked a cigarette are developing a specific type of lung cancer called adenocarcinoma. This form of the disease often grows in the outer edges of the lungs and can be cured if found early, yet current screening methods in many Asian countries rely on chest X-rays, which frequently miss these early, peripheral tumors. To address this gap, researchers are exploring whether a more advanced imaging technique, known as low-dose computed tomography, or LDCT, could save lives in this overlooked group. The challenge lies in knowing who to screen and when, as testing everyone is costly and can lead to unnecessary procedures. A new approach suggests that by combining a person's genetic makeup with their exposure to secondhand smoke, doctors could identify exactly which women are at the highest risk and determine the perfect age to start screening them.
In a recent study, a researcher named Akiko Kowada used a sophisticated computer simulation to test this idea for never-smoking women in Japan. The study did not involve real patients but instead built a virtual population of Japanese women who had never smoked. The researchers divided these virtual women into eight different groups based on two factors: their genetic risk for lung cancer, determined by a polygenic risk score which measures the cumulative effect of many small genetic variations, and their exposure to environmental tobacco smoke, such as living with a smoker or working in a smoky environment. By running millions of scenarios through a microsimulation model, the team could watch how these different groups fared over a lifetime under various screening strategies. They compared doing nothing, using standard chest X-rays, and using LDCT scans at different intervals, such as every year, every two years, or even every ten years. The goal was to find the specific age to start screening and the frequency that would save the most lives while remaining a good use of healthcare resources.
The simulation revealed that a single rule for everyone does not work for this population. Instead, the optimal time to begin screening depends heavily on a woman's specific risk profile. For women with the lowest genetic risk and no exposure to secondhand smoke, the model suggested that starting LDCT screening at age 55 was the most effective balance of benefit and cost. However, as the risk increased, the recommended starting age dropped significantly. For women with high genetic risk who were also exposed to secondhand smoke, the simulation indicated that screening should begin as early as age 40. The study found that annual LDCT screening was the most effective strategy across all risk groups. In the highest-risk groups, this approach was so effective that it actually saved money compared to doing nothing or using X-rays, because it prevented expensive late-stage treatments by catching the disease early. In the lowest-risk group, the cost was still reasonable, amounting to about US$40,471 for every year of healthy life gained.
When the researchers looked at the broader impact, the numbers were striking. Over a lifetime, switching from the current standard of annual chest X-rays to annual LDCT screening for these never-smoking women would prevent more than 8,500 deaths from lung adenocarcinoma. If compared to having no screening at all, the number of lives saved would rise to nearly 15,000. The study also highlighted that the current guidelines, which often exclude never-smokers entirely or rely on X-rays, are missing a critical opportunity. The simulation showed that the combination of genetic susceptibility and involuntary exposure to smoke creates a risk level that can match or even exceed that of moderate smokers, yet these women are currently left out of screening programs. The model remained robust even when the researchers tweaked the numbers to account for uncertainty, confirming that the recommendation for earlier screening in high-risk groups holds true.
This research suggests a path toward a more precise and equitable way to prevent lung cancer. By tailoring the start age of screening to an individual's specific genetic and environmental risks, healthcare systems could catch the disease when it is most treatable. The study points out that women who are socially vulnerable and more likely to be exposed to secondhand smoke in their homes or workplaces are the ones who would benefit most from starting screening earlier. While the study was a simulation and not a clinical trial, it provides strong evidence that the old rule of screening only based on smoking history is insufficient for the modern landscape of lung cancer in Asia. The findings urge policymakers to consider integrating genetic testing and smoke exposure history into future guidelines, ensuring that the women who need protection the most are not left behind.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.